Actinium Pharmaceuticals (ATNM) Given a $6.00 Price Target by Roth Capital Analysts
Roth Capital set a $6.00 price target on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research report report published on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages have also recently commented on ATNM. B. Riley set a $3.00 target price on Actinium Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, August 15th. Maxim Group reaffirmed a buy rating and issued a $3.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, August 14th. Zacks Investment Research cut Actinium Pharmaceuticals from a buy rating to a hold rating in a report on Monday, December 3rd. Finally, Oppenheimer set a $5.00 target price on Actinium Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, November 28th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Actinium Pharmaceuticals currently has an average rating of Buy and an average target price of $3.55.
Shares of Actinium Pharmaceuticals stock opened at $0.46 on Tuesday. Actinium Pharmaceuticals has a one year low of $0.33 and a one year high of $0.87.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
See Also: Intrinsic Value
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.